NKGEN BIOTECH, INC. – Trademark Portfolio
Entity Type: 03
NKGEN BIOTECH, INC. holds 4 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 35 (Advertising & Business) — 3 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 3 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include SUPERNK and NKGEN BIOTECH. The owner is based in Gyeonggi-do.
Cheoncheon-dong,Res&Bus Foundation Ctr
85313ho,2066,Seobu-ro,Jangan-gu,Suwon-si
Gyeonggi-do 16419 , KR
Showing of trademarks Trademarks
Trademark Classifications
NKGEN BIOTECH, INC.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Advertising; business management; business administration; office functions
Scientific and technological services; industrial analysis and research services
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does NKGEN BIOTECH, INC. have?
NKGEN BIOTECH, INC. has 4 U.S. trademarks filed with the USPTO. Of these, 3 registered, 1 cancelled.
What trademark classes does NKGEN BIOTECH, INC. file in?
NKGEN BIOTECH, INC. files trademarks across 3 Nice Classification classes. The most active classes are Class 35 (Advertising & Business), Class 42 (Computer & Scientific), Class 5 (Pharmaceuticals). Class 35 covers advertising; business management; business administration; office functions.
What are NKGEN BIOTECH, INC.'s most well-known trademarks?
NKGEN BIOTECH, INC.'s registered trademark portfolio includes well-known marks such as SUPERNK and NKGEN BIOTECH. These are among 3 currently registered trademarks in the portfolio.
What is NKGEN BIOTECH, INC.'s trademark registration success rate?
NKGEN BIOTECH, INC. has a 75% trademark registration rate, with 3 out of 4 resolved applications resulting in successful registration. Currently, 0 applications are pending review.